[1]叶阿里,张海燕,窦亚玲,等.基质辅助激光解吸电离飞行时间质谱技术检测药物代谢酶基因多态性平台的建立[J].现代检验医学杂志,2016,31(05):30-33.[doi:10.3969/j.issn.1671-7414.2016.05.008]
　YE A-li,ZHANG Hai-yan,DOU Ya-ling,et al.Establishment of MALDI TOF-MS Technique Platform for Detecting Cytochrome P450 Gene Polymorphism[J].Journal of Modern Laboratory Medicine,2016,31(05):30-33.[doi:10.3969/j.issn.1671-7414.2016.05.008]
点击复制

基质辅助激光解吸电离飞行时间质谱技术检测药物代谢酶基因多态性平台的建立()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年05期
页码:
30-33
栏目:
论著
出版日期:
2016-10-21

文章信息/Info

Title:
Establishment of MALDI TOF-MS Technique Platform for Detecting Cytochrome P450 Gene Polymorphism
文章编号:
1671-7414(2016)05-030-04
作者:
叶阿里1; 张海燕2; 窦亚玲1; 孔令君1; 张 睿1; 张晓峰2
1.中国医学科学院北京协和医学院北京协和医院检验科,北京100730;
2.北京毅新博创生物科技有限公司,北京 102206
Author(s):
YE A-li1; ZHANG Hai-yan2; DOU Ya-ling1; KONG Ling-jun1; ZHANG Rui1; ZHANG Xiao-feng2
1.Department of Clinical Laboratory,Peking Union Medical College Hospital, Chinese Academy of Medical Sciences,Peking Union Medical Collage,Beijing100730,China;
2.Bioyong(Beijing)Technologies Inc.Ltd.Beijing,102206,China
关键词:
药物代谢酶基因;  基质辅助激光解吸电离飞行时间质谱技术;  单核苷酸多态性
分类号:
R503; Q786
DOI:
10.3969/j.issn.1671-7414.2016.05.008
文献标志码:
A
摘要:
目的 建立基于基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)技术检测患者体内药物代谢酶基因多态性的平台。方法 选取2013年10月～2014年6月在北京协和医院门诊就诊患者53例EDTA抗凝外周血,提取全血基因组DNA,用MALDI-TOF-MS技术检测53例患者药物代谢酶基因CYP2C9*2(rs1799853),CYP2C9*3(rs1057910),CYP2C19*2(rs4244285),CYP2C19*3(rs4986893),CYP2C19*4(rs28399504),CYP2C19*5(rs56337013)和CYP2C19*17(rs12248560)的单核苷酸多态性(SNP)位点,并用Sanger测序法进行验证。结果 用 MALDI-TOF-MS 技术可以同时完成53份样本,2个药物代谢酶基因,7个SNP位点的检测。53例患者中,发现CYP2C19*2(rs4244285)AG型25例,AA型6例,GG型22例,A等位基因频率为34.9%。CYP2C19*3(rs4986893)AG型4例,GG型49例,A等位基因频率为3.8%。CYP2C9*3(rs1057910)CA型5例,AA型48例,C等位基因频率为4.7%。未发现 CYP2C9*2(rs1799853),CYP2C19*4(rs28399504),CYP2C19*5(rs56337013)和CYP2C19*17(rs12248560)位点突变。经与Sanger测序法比较,两种检测方法结果的符合率为100%。结论 成功建立MALDI-TOF-MS技术检测药物代谢酶基因多态性的平台,该平台具有高通量、准确的特点,对个性化用药治疗具有重要的临床应用价值。
Abstract:
Objective To establish the MALDI-TOF-MS technique platform for detecting Cytochrome P450 gene polymorphismfrom of patients.Methods Collected 53 EDTA anticoagulation peripheral blood samples from October 2013 to June 2014 in Peking Union Medical College Hospital.The whole genomic DNA was extracted from patients' peripheral blood.Used MALDI-TOF-MS to identify the SNP polymorphism of CYP2C9*2(rs1799853),CYP2C9*3(rs1057910),CYP2C19*2(rs4244285),CYP2C19*3(rs4986893),CYP2C19*4(rs28399504),CYP2C19*5(rs56337013)and CYP2C19*17(rs12248560).To verify the above SNP polymorphism by Sanger sequencing method.Results The MALDI-TOF-MS could perform 53 samples on two cytochrome gene and 7 SNP locus simultaneously.In all the 53 patients,25 AG,6 AA and 22 GG genotypes were identified in CYP2C19*2(rs4244285),the allele frequency of A genotype was 34.9%.4 AG and 49 GG genotypes were identified in CYP2C19*3(rs4986893),the allele frequency of A genotype was 3.8%.5 CA and 48 AA genotypes were identified in CYP2C9*3(rs1057910),the allele frequency of C genotype was 4.7%.No mutation loci were identified in CYP2C9*2(rs1799853),CYP2C19*4(rs28399504),CYP2C19*5(rs56337013)and CYP2C19*17(rs12248560).All the identification data were confirmed by Sanger sequencing.The coincidence rate was 100%.Conclusion The MALDI-TOF-MS technique platform for the cytochrome enzyme SNP was established.This platform has high throughput and accurate characteristics.It has important clinical application value for the treatment of personalized medicate.

参考文献/References:

[1] McDonnell AM,Dang CH.Basic review of the cyto-chrome p450 system[J].Journal of the Advanced Practitioner in Oncology,2013,4(4):263-268.
[2] Zanger WM,Schwab M.Cytochrome P450 enzymes in drug metabolism regulation of gene expression,enzyme activities,and impact of genetic variation[J].Pharmacology & Therapeutics,2013,138(1):103-141.
[3] Preissner SC,Hoffmann MF,Preissner R,et al.Polymorphic cytochrome P450 enzymes(CYPs)and their role in personalized therapy[J].PLoS One,2013,8(12):e82562.
[4] Zanger UM,Klein K,Thomas M,et al.Genetics,epigenetics,and regulation of drug-metabolizing cytochrome p450 enzymes[J].Clinical Pharmacology andTherapeutics,2013,95(3):258-261.
[5] Chang M,Tybring G,Dahl ML,et al.Impact of cyto-chrome P450 2C19 polymorphisms on citalopram/escitalopram exposure:a systematic review and meta-analysis[J].Clinical Pharmacokinetics,2014,53(9):801-811.
[6] Shahabi P,Siest G,Meyer UA,et al.Human cytoch-rome P450 epoxygenases:variability in expression and role in inflammation-related disorders[J].Pharmacology and Therapeutics,2014,144(2):134-161.
[7] Nakahashi H,Yamamura Y,Usami A,et al.Metabo-lism of(-)-cis-and(-)-trans-rose oxide by cytochrome P450 enzymes in human liver microsomes[J].Biopharmaceutics & Drug Disposition,2015,36(9):565-574.
[8] Uehara S,Inoue T,Utoh M,et al.Simultaneous pha-rmacokinetics evaluation of human cytochrome P450 probes,caffeine,warfarin,omeprazole,metoprololand midazolam,in common marmosets(Callithrix jacchus)[J].Xenobiotica,2016,46(2):163-168.

备注/Memo

备注/Memo:

作者简介:叶阿里(1974-),女,学士,检验技师,Tel:13901326309,E-mail:13901326309@163.com。
通讯作者:窦亚玲,E-mail:douyling@163.com。
更新日期/Last Update: 2016-10-30